Tel: +44 (0)1223 316 855
life science research products, biological research products, biotechnology
close ...


Supplier:
Product types:
Cardiosight-S®
GLP Compliant Safety Pharmacology Services
Rapid & Sensitive 8-OHdG Quantification

Get More Reliable & Robust Results In Gene Silencing With siPOOL™

APD testing with iPSC human cardiomyocytes

Cambridge Bioscience offers access to an action potential assay (APA) service on induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) from B’SYS. This animal-free assay provides a more accurate indicator of cardiac risk, at a much earlier stage in drug discovery and development, than previously available approaches. The use of iPSC-CMs provides a unique opportunity to study the effects on cardiac excitability and rhythm of potential therapeutic compounds directly on human ventricular-type myocytes not typically available for routine testing.

Benefits of using iPSC-CMs
• Higher sensitivity using lower amounts of drug
• Better correlation between preclinical and clinical studies
• Higher throughput screening
• Rapid turnaround time
• Cost savings in an animal-free assay

Features of the SC-hCM APD assay
• Detects AP Prolongation, a risk factor for LQTS, EADs and Torsades de Points
• Stable recordings at physiological temperature with minimal diffusion delays
• Cost-effective compared to conventional methodologies
• Human cell line provides accurate preclinical results

Request a quote
To discuss a cardiomyocyte action potential assay project, please contact our B'SYS specialist.

Contact Our B'SYS Specialist, Vashu